Evidence map›Paper›PMID 40596281›Full record

ArticleScientific reports2025

In vitro evaluation of mesalazine enteric-coated tablet dissolution by the reciprocating cylinder method.

Jinxiang Wang, Yanqing Zhao, Gaihua He, Bin Guo, Hui Zhang

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jinxiang WangJinzhou Medical University, Jinzhou city, 121000, China.
Yanqing ZhaoJinzhou Medical University, Jinzhou city, 121000, China.
Gaihua HeElite Pharmatech Company, Shanghai city, 201210, China. ghhe2020@yeah.net.
Bin GuoJinzhou Medical University, Jinzhou city, 121000, China.
Hui ZhangElite Pharmatech Company, Shanghai city, 201210, China.

Funding

National Natural Science Foundation of China 52402118
6 · The paper itself

Abstract

Mesalazine formulations are first-line treatments for ulcerative colitis. However, the drug release mechanisms of currently available mesalazine formulations on the market vary, and different in vitro dissolution methods have been used to characterize their in vivo absorption. Thus, there is an urgent need for more in-depth research on in vitro dissolution methods for mainstream mesalazine enteric-coated tablets. The goal of this study is to determine more scientifically rigorous testing methods to enhance the discriminatory power of in vitro dissolution testing of these products. Dissolution tests were performed using the reciprocating cylinder method with a small 250 ml vessel, a reciprocating frequency of 10 cycles/min, a sample volume of 5 ml, and UV spectrophotometric detection. The absorbance values of the dissolution solutions at different pH values were measured using cuvettes with path lengths of 1 cm and 1 mm and at detection wavelengths of 303 nm and 332 nm, respectively. In pH 1.2, 4.5, 5.5, and 6.0 solutions, the linear concentration range was from 5 to 30 µg/ml. In contrast, the linear concentration range in pH 6.8 media was 90 to 660 µg/ml. Method accuracy was tested at levels of 5%, 50%, 100%, and 120%, and the average recovery rates were 105.8%, 102.8%, 100.9%, and 101.2%, respectively. Moreover, the differences in the dissolution data did not exceed 2% with different instruments or analysts or on different days. Using the reciprocating cylinder method, we continuously measured the dissolution of mesalazine enteric-coated tablets in media with various pH values that simulate different sections of the human digestive system. Furthermore, in pH 6.8 dissolution media, drug release from both the homemade and the reference formulations followed zero-order kinetics. The established reciprocating cylinder method for determining the dissolution of mesalazine enteric-coated tablets is suitable for quality control of this type of product.

Indexed as

Anti-Inflammatory Agents, Non-SteroidalMesalamineTablets, Enteric-CoatedChemistry, PharmaceuticalDrug LiberationHumansHydrogen-Ion ConcentrationSolubilityTabletsAnti-Inflammatory Agents, Non-SteroidalMesalamineTabletsTablets, Enteric-CoatedDissolution in vitroMesalazine enteric-coated tabletsMethodology development and validationReciprocating cylinder method

Identifiers

PMID40596281
PMCPMC12219704

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.